
New chairman for Egenix
pharmafile | December 23, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â egenix, lionel goldfrankÂ
Lionel Goldfrank has been elected to sit on the board of the US-based biotech firm Egenix.
Goldfrank is to succeed Donald Fresne at the New York company who has also resigned as president and chief executive, but will continue as a member of the board.
In recognition of the contributions and value Fresne has added to the company for over almost 20 years, it says he has now been designated as chairman emeritus.
Egenix is a privately-held biotechnology company focussed on the development of cancer therapeutics.
The company’s therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer’s.






